On January 7, 2019 Epigenomics AG (FSE: ECX, OTCQX: EPGNY) reported that a microsimulation model has been completed by external academic experts demonstrating positive results for the Epi proColon blood test (Press release, Epigenomics, JAN 7, 2019, View Source [SID1234532559]). The manuscript is being finalized and will be submitted for publication soon. Epigenomics will discuss the specific findings once the manuscript is published.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Microsimulation models have been used to project the harms and benefits of various strategies for Colorectal Cancer Screening (CRC). These models are utilized by various screening guideline groups such as the United States Preventative Services Task Force (USPSTF) and the American Cancer Society to aid in the development of screening guidelines. To date, none of the previously completed models used for guideline development have incorporated the methylated Septin 9 blood test (Epi proColon) as one of the strategies. The model just completed incorporates the Epi proColon test and also factors in the key variable of adherence to testing. Adherence to testing is a critical element for the improvement of screening rates, and blood based testing holds promise for the approximately 35% of eligible people not up to date for screening according to the guidelines.